Abstract
Irinotecan (CTP-11) is a topoisomerase I inhibitor used in the treatment of colorectal cancer and non-small cell lung cancer (NSCLC). Despite an initial response to therapy, resistance to irinotecan reduces its efficacy. We isolated irinotecan-resistant human NSCLC A549 cells, termed A549/CTP-11R cells. A549/CTP-11R cells were resistant to irinotecan, as well as paclitaxel, gemcitabine and carboplatin. Curcumin, a nuclear factor-κB (NF-κB) inhibitor, increased the sensitivity to irinotecan of A549/CTP-11R cells. The expression level of Bcl-XL and X-linked inhibitor of apoptosis protein, target genes of NF-κB, in A549/CTP-11R cells was higher than that in A549 cells. Our result suggests that the addition of curcumin to irinotecan reverses irinotecan resistance in NSCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 1031-1034 |
| Number of pages | 4 |
| Journal | Molecular Medicine Reports |
| Volume | 3 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Bcl-X
- Curcumin
- Irinotecan
- Non-small cell lung cancer
- X-linked inhibitor of apoptosis protein
ASJC Scopus subject areas
- Biochemistry
- Molecular Medicine
- Molecular Biology
- Genetics
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver